HRA Pharma Sharpens Focus On OTC With Rare Diseases Split
By shifting its rare diseases portfolio into a newly-created affiliate, HRA Pharma is signalling its intention to become a force in the global consumer healthcare market.
You may also be interested in...
Paris-based HRA Pharma reported significant sales gains for its key consumer health brands in 2021, helping to lift group turnover by more than 25%. This is likely to be the last set of results posted by HRA as a standalone company with Perrigo optimistic its proposed acquisition of the firm will soon complete.
HRA is putting feet on the ground in China as it looks to establish itself in the world second-largest consumer health market.
France's HRA is looking to tap into consumer demand for foot care products in the Middle East by rolling out its Compeed brand in select markets across the region.